Dr. Michael David Rosenblum, MD, PhD

Dr. Rosenblum practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Dr. Rosenblum's NPI, 1356521603, was assigned on November 4, 2007. Dr. Rosenblum graduated from Medical College Of Wisconsin in 2006. Dr. Rosenblum's California license number on file is A101640.

Dr. Rosenblum's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Dr. Rosenblum's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Dr. Rosenblum to 2 more group practices and clinics and 2 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Rosenblum practices, 3 sites in all. Vendor and product names are available with a free account.

Dermatology is Dr. Rosenblum's primary specialty in the NPI Registry, under taxonomy code 207N00000X. Dr. Rosenblum is board certified in dermatology by the American Board of Dermatology. Dr. Rosenblum has a license on file in California.

Dmand AI lists itchy rashes among the conditions Dr. Rosenblum treats.

CMS data shows 66 Medicare services from Dr. Rosenblum across 2 procedure codes in 2024, all of them office visits, for 58 Medicare patients. Medicare paid $4,493 for them. Every service was in an office.

CMS counts 58 Medicare patients who saw Dr. Rosenblum in 2024. The largest group is 65 to 74, with 24 patients. 59% of them have high blood pressure, and 55% have high cholesterol. 45% are also on Medicaid. Their average risk score is 1.85, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Rosenblum's median patient age at 67, with 64% women.

In 2024, Dr. Rosenblum wrote 203 Medicare Part D claims for 49 patients. 92% of them were for generic drugs. CMS names the drug for 118 of them, across 6 drugs with 11 or more claims each, at $2,629 in total drug cost. In 2022, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Dr. Rosenblum for performance year 2024, reported as part of a group. Dr. Rosenblum accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Rosenblum as offering telehealth.

Removal of skin lesions: 1 to 10 procedures (CMS shows small counts as a range)

Skin biopsy: 1 to 10 procedures (CMS shows small counts as a range)

Dmand AI links 107 papers to Dr. Rosenblum, published from 2003 to 2024. 2017 was the busiest year, with 10. The most frequent topics are T-Lymphocytes, Regulatory, Skin and Mice, Inbred C57BL. Dr. Rosenblum has published most often in Sci Immunol. Dr. Rosenblum's most frequent co-authors are Abul K. Abbas, MBBS, Jarish Cohen and Tiffany Crawford Scharschmidt, MD.

CMS Open Payments shows 87 general payments to Dr. Rosenblum from 14 drug and device companies from 2016 to 2025. Consulting fees make up the largest share, 98% of the total. Celgene Corporation paid the most, $125,417. It also lists 3 research payments totaling $118,024 from 2017 to 2019.

Dr. Rosenblum graduated from Medical College Of Wisconsin in 2006.

Dr. Rosenblum is in network with 9 carriers, including Aetna, Blue Cross Blue Shield of Michigan and Blue Cross Blue Shield of Massachusetts. Medicare plans come from the most carriers, 8. Check the plan with the practice before a visit.